Alvotech Swiss AG
- Address
- Thurgauerstrasse 54
Sponsor Overview
Specializations
Gastroenterology and Inflammatory Bowel Disease
Clinical research includes moderate to severe active ulcerative colitis, with interest in biologic treatment pathways and biosimilar development for immune-mediated intestinal inflammation.
- Ulcerative colitis
- Biologic therapy
- Biosimilar medicines
The sponsor’s work in this area is centred on therapeutic options for chronic gastrointestinal inflammation and related immune disease management.
Retinal Diseases and Ophthalmology
Research activity spans diabetic macular edema and broader chorioretinal vascular disease, including conditions associated with retinal fluid accumulation and vascular leakage.
- Diabetic macular edema
- Retinal vascular disease
- Ophthalmic safety
These studies reflect a focus on eye disorders that affect central vision and retinal structure, particularly in diabetic and vascular settings.
Neovascular Eye Disease
Clinical interest extends to neovascular age-related macular degeneration, myopic choroidal neovascularization, retinal vein occlusion, and diabetic retinopathy, covering major causes of sight-threatening retinal neovascularisation.
- Neovascular age-related macular degeneration
- Myopic choroidal neovascularization
- Retinal vein occlusion
- Diabetic retinopathy
The therapeutic emphasis in this domain is on retinal vascular disorders with a shared pathophysiology of abnormal blood vessel growth and macular involvement.
Biosimilar Development in Specialty Therapeutics
The sponsor’s portfolio includes comparative clinical research for biosimilar candidates across gastroenterology and ophthalmology, supporting treatment areas where targeted biologic therapies are established.
- Comparative efficacy
- Ocular safety
- Specialty biologics
This research landscape connects immune-mediated bowel disease with retinal vascular disorders through the evaluation of advanced therapeutic alternatives.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Randomized, Double-masked Study Comparing the Efficacy and Safety of AVT29 Versus High-Dose Aflibercept in Participants with Diabetic Macular Edema |  Bulgaria Czechia Hungary Latvia Poland Slovakia | Recruiting |
| Comparative Efficacy, Safety, and Immunogenicity of Intravenous AVT16 Versus Vedolizumab in Adults with Moderate to Severe Active Ulcerative Colitis | Bulgaria Croatia Czechia Greece Hungary Italy Latvia Poland Romania Slovakia Spain | Not Recruiting |
| Evaluation of Handling and Ocular Safety of Aflibercept Pre-Filled Syringe in Chorioretinal Vascular Diseases: A Single-Arm, Open-Label, Multicenter Study | Latvia | Not Recruiting |
Data & Insights
This sponsor works with 3 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 141 sites across their trial portfolio.
Therapeutic Focus
- 1.Eye Diseases2 trials138 other sponsors
- 2.Digestive System Diseases1 trial280 other sponsors
Partnered Research Centres
141 centres- Address
- Ul. Rudolfa Weigla 5, 53-114 Wroclaw
- Address
- Vassilissis Sofias Avenue 80, 115 28 Athens
- Address
- Ul. Zgierska 249, 91-495 Lodz
- Address
- Ostrovskeho 253/3, Smichov, 150 00 Prague
- Address
- Via Ferdinando Magellano 1, 10128 Turin
- Address
- Via Trabucco 180, 90146 Palermo
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Alvotech Swiss AG.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.